Potential of NOTCH1 Mutation to Predict Anti-PD1 Treatment Outcomes in Patients with Oesophageal Squamous Cell Cancer By Ogkologos - April 23, 2025 632 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a biomarker analysis from the RATIONALE-302 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Cómo solicitar Medicare cuando tiene cáncer December 12, 2023 FDA Approves Durvalumab for Locally Advanced or Metastatic Biliary Tract Cancer September 14, 2022 FDA Approves Penpulimab-kcqx for Non-keratinizing Nasopharyngeal Carcinoma May 23, 2025 Foodie Friday: What to do with all these zucchini? July 9, 2021 Load more HOT NEWS Trial Confirms CAR T-Cell Therapy Benefits People with Aggressive Lymphomas Single Mom Has To Beg For Rides To Doctor For Son... The digital shift: How are remote GP appointments affecting cancer patients? Julia Louis-Dreyfus Talks About The Side Effects of Chemotherapy
